Mandate

Vinge advised Creades on its investment in Apotea

April 28, 2017

Creades AB (publ) (Nasdaq Stockholm) has purchased 4.9 per cent of the shares in Apolea Holding AB, which is the parent company (96.5%) of the Internet pharmacy Apotea AB.

The investment by Creades amounts to a total of SEK 120.5 million.
 
Vinges team consisted of Erik Sjöman and Jesper Ottergren.
 

Related

Vinge has advised Eleda in connection with the acquisition of Sartor & Drange AS

Vinge, together with Thommessen, advised the infrastructure group Eleda in connection with the acquisition of Sartor & Drange AS, a market-leading civil engineering contractor in the Bergen region. Sartor & Drange AS offers services in areas such as road, water and sewerage and foundation work in Western Norway. Sartor & Drange AS has approximately 200 employees and a turnover of approximately NOK 1,100 million.
June 17, 2024

Vinge has advised Svea Bank AB in connection with the issuance of callable tier 2 capital bonds (T2) of SEK 300 million

Vinge has advised Svea Bank AB in connection with its issuance of SEK 300 million callable tier 2 capital bonds (T2) with a floating rate interest of 3-month STIBOR + 6.75%. The issue date is set to 7 June 2024, and the bonds have a maturity of 10.25 years with first permitted redemption date after 5 years. The instruments will be listed on Nasdaq Stockholm.
June 14, 2024

Vinge advises Axcel and XPartners in connection with the acquisition of HTJ

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of HTJ Holding OY and its subsidiary Rakennuttajatoimisto HTJ Oy (”HTJ”).
June 13, 2024